Allakos Secures $100 Million In Series B FinancingProceeds will support advancement of AK002 in five disease areas Lead clinical program evaluating AK002 in eosinophilic gastroenteritis, an inflammatory gastrointestinal disease SAN CARLOS, Calif., December 13, 2017-- Allakos Inc., a private, clinical-stage biopharmaceutical company focused on the development of antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced the successful completion of a $100 million Series B equity financing.